The aim of this review is to summarize our knowledge and present current insights into the mechanisms of KMT2A-rearranged (KMT2A-r) ALL, portray their characteristics, discuss the clinical outcomes along with risk stratification, and present novel therapeutic strategies. Here, KMT2A is linked to acute lymphoblastic leukemia.